X4 Pharma
NASDAQ: XFORBoston, US · Founded 2014 · 78 employees on LinkedIn · 7 known investors
Find your way into X4 Pharma
290 people in our graph share verified history with the X4 Pharma team — schools, employers, funds. One of them is your warm intro.
Sandra Schwarzerunlockedknows Mary DiBiase · together at University of London
×2knows the team · via University of Rhode Island
×5knows the team · via University of London
×3knows the team · via Bentley University - McCallum Graduate School of Business
knows the team · via Seattle University
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia. It is a publicly traded company listed on Nasdaq.
Founders & leadership
MD
Mary DiBiaseinChief Operating Officer2021–2025Mary DiBiase is an executive operations leader with experience in biopharmaceutical development and commercialization across multiple therapeutic areas. She has served on executive leadership teams at various organizations, directing corporate strategy and organizational growth.
CA
Christophe Arbet-EngelsinChief Medical Officer2023–2025Christophe Arbet-Engels is an executive with extensive pharmaceutical industry experience spanning drug discovery through commercialization across multiple therapeutic areas including cardiovascular-metabolism and oncology. He leads X4 Pharmaceuticals, a Nasdaq-listed biopharmaceutical company developing treatments for rare immune disorders.
DK
David KirskeinChief Financial OfficerDavid Kirske is an executive officer at X4 Pharmaceuticals, a publicly traded biopharmaceutical company developing treatments for rare immune disorders. He has held senior financial and operational roles in life sciences and technology companies across public and private sectors.
JV
John VolponeinPresident and Chief Operating OfficerJohn Volpone is an Executive Officer at X4 Pharmaceuticals, a publicly traded biopharmaceutical company developing treatments for rare immune disorders. He has held roles across pharmaceutical, biotech, medical device, and industrial engineering sectors, with experience in strategic development, licensing negotiations, and stakeholder management.
MB
Mark BaldryExecutive
AC
Adam CraiginExecutive ChairmanAdam Craig is Chief Executive Officer and Board Chair of X4 Pharmaceuticals, a publicly traded biopharmaceutical company developing treatments for rare immune disorders. He brings over 35 years of experience in healthcare and biotechnology.
TU
Tillman U GerngrossNamed on SEC filing
EN
Eszter NagyNamed on SEC filing
Board
FD
Francoise De CraeckerBoard director
CG
Carl GordonBoard director
MR
Michael RossBoard director
CN
Investors · 7
Bain Capital Life SciencesBoston
Lumira VenturesToronto · $1M – $10M
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Partners ResoluteChicago
Thynk Capitalvia Jim Plante · inferred
Omega FundsreportedBostonvia Claudio Nessi · board
Polaris PartnersreportedBoston · $500K – $5Mvia Amy Schulman · board
Reported raises · per SEC filings
Form D private placements$310.3M disclosed across 8 rounds · 2013–2025
▶$85MraisedAug 2025 · 18 investors · BiotechnologyRule 506(b)
▶$85MraisedAug 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mary DiBiaseExecutive Officer
- Murray W. StewartDirector
- Christophe Arbet-EngelsExecutive Officer
- David KirskeExecutive Officer
- Michael S. WyzgaDirector
- John VolponeExecutive Officer
- Mark BaldryExecutive Officer
- Francoise De CraeckerDirector
- Gary J. BridgerDirector
- Adam CraigExecutive Officer, Director
- Offering amount
- $85M
- Amount sold
- $85M
- Sales commissions
- $3.3M
- Placement agents
- STIFEL, NICOLAUS & COMPANY, INCORPORATED
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$65MraisedJun 2023 · 22 investors · BiotechnologyRule 506(b)
▶$65MraisedJun 2023 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David McGirrDirector
- Francoise de CraeckerDirector
- Adam MostafaExecutive Officer
- Michael WyzgaDirector
- Arthur TaverasExecutive Officer
- Mary DiBiaseExecutive Officer
- Murray StewartExecutive Officer, Director
- William AliskiDirector
- Alison LawtonDirector
- Gary BridgerDirector
- Mark BaldryExecutive Officer
- Paula RaganExecutive Officer, Director
- Offering amount
- $65M
- Amount sold
- $65M
- Sales commissions
- $4M
- Placement agents
- Cantor Fitzgerald & Co., Piper Sandler & Co., Stifel, Nicolaus & Company, Inc.
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$55.7MraisedJul 2022 · 23 investors · BiotechnologyRule 506(b)
▶$55.7MraisedJul 2022 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam S. MostafaExecutive Officer
- Arthur TaverasExecutive Officer
- David McGirrDirector
- Francoise de CraeckerDirector
- Michael S. WyzgaDirector
- Paula RaganExecutive Officer, Director
- Diego CadavidExecutive Officer
- Mary DiBiaseExecutive Officer
- Murray W. StewartDirector
- Gary J. BridgerDirector
- Derek MeisnerExecutive Officer
- Alison LawtonDirector
- William E. AliskiDirector
- Offering amount
- $111.5M
- Amount sold
- $55.7M
- Sales commissions
- $2.8M
- Placement agents
- Stifel, Nicolaus & Company, Inc.
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedDec 2017 · 1 investors · BiotechnologyRule 506(c)
▶$20MraisedDec 2017 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Amy SchulmanDirector
- Michael RossDirector
- Claudio NessiDirector
- Carl GordonDirector
- David MantusExecutive Officer
- Chris StevensExecutive Officer
- William ClarkDirector
- David McGirrDirector
- Eszter NagyExecutive Officer
- Michael GrayExecutive Officer
- Tillman U. GerngrossDirector
- Terrance McGuireDirector
- Rene RussoExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.4M
- Placement agents
- Citigroup Global Markets Inc., Cowen and Company, LLC, Piper Jaffray & Co.
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$45.5MraisedMay 2017 · 18 investors · BiotechnologyRule 506(b)
▶$45.5MraisedMay 2017 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael RossDirector
- Carl GordonDirector
- Terrance McGuireDirector
- David MantusExecutive Officer
- Rene RussoExecutive Officer, Director
- Michael GrayExecutive Officer
- Dan BurgessDirector
- Eszter NagyExecutive Officer, Director
- Amy SchulmanDirector
- Tillman U. GerngrossExecutive Officer, Director
- Jan AdamsDirector
- Chris StevensExecutive Officer
- Claudio NessiDirector
- Offering amount
- $50.5M
- Amount sold
- $45.5M
- Proceeds to insiders
- $3M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedApr 2016 · 10 investors · BiotechnologyRule 506(b)
▶$15MraisedApr 2016 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan AdamsDirector
- Carl GordonDirector
- Amy SchulmanDirector
- Terrance McGuireDirector
- Claudio NessiDirector
- Daniel BurgessDirector
- Michael GrayExecutive Officer
- Eszter NagyExecutive Officer, Director
- Michael RossDirector
- Tillman GerngrossExecutive Officer, Director
- Rene RussoExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- Proceeds to insiders
- $770K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedDec 2015 · 8 investors · BiotechnologyRule 506(b)
▶$4MraisedDec 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Claudio NessiDirector
- Amy SchulmanDirector
- Michael RossDirector
- Carl GordonDirector
- Terrance McGuireDirector
- Tillman U GerngrossExecutive Officer, Director
- Dan BurgessDirector
- Eszter NagyExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$20MraisedJun 2015 · 8 investors · BiotechnologyRule 506(b)
▶$20MraisedJun 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl GordonDirector
- Michael RossDirector
- Tillman U GerngrossExecutive Officer, Director
- Dan BurgessDirector
- Claudio NessiDirector
- Terrance McGuireDirector
- Michael RossDirector
- Eszter NagyExecutive Officer, Director
- Amy SchulmanDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Seeking Alpha28 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView23 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Perplexity22 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
TipRanks22 shared keywordsFinancial analysis and stock research platform.
Robinhood21 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits19 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall St17 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies competing with X4 Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does X4 Pharma do?
- X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia. It is a publicly traded company listed on Nasdaq.
- Who are X4 Pharma's investors?
- X4 Pharma's investors include Bain Capital Life Sciences, Lumira Ventures, New Enterprise Associates (NEA), Partners Resolute, Thynk Capital, Omega Funds, Polaris Partners.
- How much funding has X4 Pharma raised?
- X4 Pharma has disclosed $310.3M raised across 8 rounds.
- Where is X4 Pharma headquartered?
- X4 Pharma is headquartered in Boston, US.